- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00710125
Safety Study of GPX-150 in Patients With Solid Tumors
August 4, 2014 updated by: Gem Pharmaceuticals
Phase 1 Study and Dose Seeking Study of an Intravenous Formulation of the Anthracycline Analog GPX-150 in Patients With Solid Tumors
This is a Phase 1 safety and dose escalation study to define the maximum tolerated dose (MTD) and identify the dose limiting toxicities (DLT) following IV administration of GPX-150 once every 3 weeks.
Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment.
Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
27
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa Hospital and Clinics
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient is at least 18 years of age.
- Patient has a histologically or cytologically confirmed diagnosis of solid tumor.
- Patient has progressive disease
- Patient is considered to have incurable disease and is not a candidate for known effective systemic treatment.
- Patient has a performance status of at least 70% on Karnofsky scale.
- Patient has not received any cytotoxic chemotherapy or other investigational agents within 4 weeks of the first treatment in this study (6 weeks for mitomycin or nitrosourea). Patients should receive supportive care as indicated. Patients currently receiving blood transfusions or erythropoiesis-stimulating agents should continue receiving them as per the ASCO guidelines. Patients requiring palliative radiation therapy should complete their course of radiation treatment 4 weeks before the first study treatment.
- Patient may have received unlimited prior hormonal therapy, but this must have been completed at least 4 weeks prior to the first study treatment, and progressive disease documented following withdrawal of hormone therapy. Patient with hormone-refractory prostate cancer on long acting LHRH agents may continue on these agents.
- Patient may have received unlimited prior biological or immunological therapy without limitation, but this must have been completed at least 4 weeks prior to the first study treatment.
- Patient has fully recovered from any previous surgery (at least 4 weeks since major surgery) and radiation therapy (at least 4 weeks since the end of treatment).
- Patient has recovered from reversible toxicity of prior therapy. Permanent and stable side effects or changes are acceptable if ≤ to Grade 2.
- Patient has adequate hematological function as defined by an ANC ≥ 1500, platelets ≥ 100,000/µL, and hemoglobin ≥9.0 gm/dL.
- Patient has adequate organ function defined as a bilirubin ≤ 1.5 times ULN, AST and ALT < 2.5 times the upper limit of normal (ULN, 5.0 times the ULN with liver involvement), serum creatinine <2.0 dL or estimated creatinine clearance ≥ 50 ml/min.
- Patient has an ejection fraction of 110% of the lower limit of institutional normal as determined by resting MUGA scan.
- Patient has an O2 Sat by pulse oximetry of at least 90%.
- Patient has a negative pregnancy test prior to study entry if premenopausal or if less than 12 months after menopause. Premenopausal patients must use a medically effective form of contraception during the treatment period.
- Patient is willing and able to comply with all study protocol requirements. The patient or a legally authorized representative must fully understand all elements of the informed consent and have signed the informed consent according to institutional and federal regulatory requirements.
Exclusion Criteria:
- Patient is pregnant or breast-feeding.
- Patient has a history of hypersensitivity to anthracyclines.
- Patient has received a cumulative dose of doxorubicin that exceeds 300 mg/m2 or a cumulative dose of epirubicin that exceeds 540 mg/m2.
- Patient has received an anthracycline within 6 months prior to entry into the study.
- Patient has brain metastases unless asymptomatic and stable off glucocorticoids.
- Prior history of CHF, myocardial infarction within 6 months prior to enrollment, active ischemic heart disease, or uncontrolled hypertension.
- Patient requires active medical therapy for CHF or arrhythmia.
- Patients with > Grade l motor neuropathy or > Grade 2 sensory neuropathy.
- Patient has participated in a study of any investigational drug within 4 weeks prior to the first study treatment.
- Patient has received chemotherapy, hormonal therapy (with the exception of LHRH for prostate cancer), immunotherapy, biological therapy, or radiotherapy within 4 weeks prior to the first study treatment.
- Patient has had major surgery within 4 weeks of the first study treatment.
- Patient has received G-CSF or GM-CSF within 4 weeks prior to first dose of study drug.
- Patient has baseline laboratory values that are outside normal ranges or those listed (see Inclusion Criteria), which are clinically significant as determined by the investigator.
- Patient has a serious, concurrent medical condition that would limit the patient's ability to complete or comply with the study requirements.
- Patient is unable or unwilling to comply with the contraceptive requirements during the study period.
- Patient has lymphoma.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: GPX-150 for Injection
GPX-150 is administered IV on Day 1, followed by a 20 day rest period, every 3 weeks.
|
Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment.
Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Define maximum tolerated dose and identify dose limiting toxicities following IV administration of GPX-150 for Injection once every 3 weeks
Time Frame: Every 3 weeks
|
Every 3 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics and any antitumor activity
Time Frame: Every 3 weeks
|
Every 3 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Raymond J Hohl, MD, PhD, University of Iowa
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2008
Primary Completion (Actual)
October 1, 2013
Study Completion (Actual)
October 1, 2013
Study Registration Dates
First Submitted
July 2, 2008
First Submitted That Met QC Criteria
July 3, 2008
First Posted (Estimate)
July 4, 2008
Study Record Updates
Last Update Posted (Estimate)
August 5, 2014
Last Update Submitted That Met QC Criteria
August 4, 2014
Last Verified
August 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GPX-150-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumors - Phase 1 Population
-
BeiGeneRecruitingLocally Advanced or Metastatic Solid Tumors for Phase 1,Dose Escalation and Phase 2 Safety Lead-in, HNSCC, NSCLC and RCC Participants for Phase 2Australia, United States, Spain, France, Italy, Korea, Republic of, Poland
-
Johnson & Johnson Pharmaceutical Research & Development...Janssen Pharmaceutica N.V., BelgiumCompletedPharmacokinetics | Advanced Malignancies | Solid Malignancies | Protein Kinase Inhibitors | Maximum Tolerated Dose | Antineoplastic Protocols | Clinical Trial, Phase 1
-
PfizerTerminatedLocally Advanced or Metastatic Solid Tumors | Genes, BRCA 1United States, Belgium, Spain, Denmark, Japan, France, Italy, Netherlands, United Kingdom
-
Handok Inc.CMG Pharmaceutical Co. LtdCompletedSolid Tumor, Adult | Phase 1Korea, Republic of
-
AmgenCompletedCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced MalignancyUnited States, Australia
-
NantCell, Inc.CompletedQUILT-2.016: Study of AMG 479 With Biologics or Chemotherapy for Subjects With Advanced Solid TumorsCancer | Advanced Solid Tumors | Solid Tumors | Tumors | Advanced Malignancy
-
Incyte CorporationRecruitingA Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid TumorsAdvanced Solid Tumors | Solid Tumors | Metastatic Solid TumorsUnited States, Spain, United Kingdom, France, Italy, Denmark, Switzerland
-
Epizyme, Inc.CompletedB-cell Lymphomas (Phase 1) | Advanced Solid Tumors (Phase 1) | Diffuse Large B-cell Lymphoma (Phase 2) | Follicular Lymphoma (Phase 2) | Transformed Follicular Lymphoma | Primary Mediastinal Large B-Cell LymphomaAustralia, Canada, France, Germany, Italy, Poland, Taiwan, Ukraine, United Kingdom, United States
-
Agenus Inc.CompletedAdvanced Solid Cancers | Advanced Solid Cancers Refractory to PD-1United States
-
Hoffmann-La RocheCompletedSolid Tumors, Advanced Solid TumorsUnited States
Clinical Trials on GPX-150 for Injection
-
Gem PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedAnkylosing SpondylitisJapan
-
National Institute of Allergy and Infectious Diseases...AbbVieActive, not recruitingHIV-1-infectionUnited States
-
Yuhan CorporationRecruitingAllergic Disease | Chronic Spontaneous Urticaria | Cold Urticaria | Chronic Inducible UrticariaKorea, Republic of
-
Bio-Thera SolutionsNot yet recruiting
-
Yuhan CorporationRecruitingAtopic Healthy Subjects | Adult Subjects With Mild Allergic DiseasesKorea, Republic of
-
Suzhou Connect Biopharmaceuticals, Ltd.CompletedHealthy Adult SubjectsChina
-
Shanghai Gebaide Biotechnology Co., Ltd.UnknownNon-small-cell Lung Cancer (NSCLC) Stage IVChina
-
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Not yet recruiting
-
University of NebraskaSuspended